LONDON–(BUSINESS WIRE)– #aiml–Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ve…
Author: Business Wire
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the su…
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that the U.S. Food and Drug Administration (F…
Riassunto: Novaliq ottiene l'autorizzazione IND dalla FDA per far avanzare NOV05 in una sperimentazione clinica di Fase II sull'uveite anteriore non infettiva
HEIDELBERG, Germania e CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, un’azienda biofarmaceutica specializzata in terapie oculari di prima classe e all’avanguardia basate sulla sua esclusiva categoria di farmaci EyeSol® senza acqua, ha annunciato …
Resumen: Novaliq recibe la autorización de la FDA para la IND y avanza con NOV05 en un ensayo clínico de Fase II en uveítis anterior no infecciosa
HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, una compañía biofarmacéutica enfocada en el desarrollo de terapias oftálmicas pioneras y de primera categoría, basadas en su exclusiva plataforma de fármacos sin agua EyeSol®, a…
Novaliq obtient l'autorisation de l’IND de la FDA pour faire progresser le NOV05 dans un essai clinique de phase II sur l'uvéite antérieure non infectieuse
HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, une société biopharmaceutique spécialisée dans les traitements oculaires de première classe et les meilleurs de leur catégorie, basés sur sa catégorie unique de médicaments sa…
Novaliq erhält IND-Zulassung der FDA zur Anwendung von NOV05 in einer klinischen Phase-II-Studie zu nicht-infektiöser anteriorer Uveitis
HEIDELBERG, Deutschland und CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Novaliq, ein Biopharmaunternehmen mit Schwerpunkt auf First- und Best-in-Class-Augentherapeutika, die auf der einzigartigen wasserfreien EyeSol®-Technologie basieren, gab heute beka…
Samenvatting: Novaliq ontvangt FDA-goedkeuring voor IND-aanvraag om NOV05 naar een fase II-klinische studie naar niet-infectieuze anterieure uveïtis te brengen
HEIDELBERG, Duitsland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novaliq, een biofarmaceutisch bedrijf dat zich toelegt op first-in-class en best-in-class oculaire therapieën op basis van zijn unieke watervrije Eyesol®-geneesmiddelencategorie, kondigde vanda…
Novaliq获FDA IND许可推进NOV05用于非感染性前葡萄膜炎的II期临床试验
德国海德堡&美国马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)– Novaliq是一家生物制药公司，专注于基于其独有的无水EyeSol®药物技术体系，开发同类首创及同类最优的眼科治疗方案。公司今日宣布，美国食品药品监督管理局（FDA）已完成对其NOV05研究性新药（IND）申请的审评并予以放行。这是Novaliq首个用于治疗内眼疾病的IND申请。 NOV05是一款基于EyeSol®递送体系的他克莫司眼用溶液，属于创新性的无类固醇外用抗炎治疗方案。本次IND获FDA放行，使公司…
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce les résultats de son Assemblée Générale Extraordinaire du 28 janvier 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des m…
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S….
Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–FDA fast tracks DF-003 for ROSAH syndrome, announces Drug Farm.
Personalized Ophthalmology Therapies Market Report 2025: $5.46 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Personalized Ophthalmology Therapies Market Report 2025” has been added to ResearchAndMarkets.com’s offering. The personalized ophthalmology therapies market is experiencing significant growth, with an expected increase fr…
Following Merger, Advancing Sight Network and Miracles In Sight Become Precision Ocular Network
BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today announced Precision Ocular Network as the new name and brand of their combined organization, following the merger unveiled in November. The new iden…
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the spe…
Qlaris Bio Appoints Robert Warner to Board of Directors
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment c…
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis
HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #FDA–Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and D…
Johnson & Johnson reports Q4 and Full-Year 2025 results
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” …
Alcon Completes $750 Million Share Repurchase Program
GENEVA–(BUSINESS WIRE)–Alcon Completes $750 Million Share Repurchase Program